Sanyal AJ, Bedossa P, Fraessdorf M, et al, for the 1404-0043 Trial Investigators* Published June 7, 2024 N Engl J Med 2024;391:311-319 DOI: 10.1056/NEJMoa2401755 Πατώντας
Rohit Loomba, M.D., Mark L. Hartman, M.D., Eric J. Lawitz, M.D., et al, for the SYNERGY-NASH Investigators* Published June 8, 2024 N Engl J Med
Published July 31, 2024 N Engl J Med 2024;391:475-476 DOI: 10.1056/NEJMc2402341 Πατώντας ΕΔΩ μπορείτε να δείτε την περίληψη του άρθρου
Dongelmans EJ, Hirode G, Hansen BE, Chen CH, Su TH, Seto WK, Furquim d’Almeida A, van Hees S, Papatheodoridi M, Lens S, Wong GLH, Brakenhoff
Lam Laurent et al, on behalf of the Global & ERN Rare-Liver PBC Study Groups. Clinical Gastroenterology and Hepatology, (2024) Πατώντας ΕΔΩ μπορείτε να δείτε
Grebely J, Matthews S, Causer LM, Feld JJ, Cunningham P, Dore GJ, Applegate TL. We have reached single-visit testing, diagnosis, and treatment for hepatitis C
Pol S, Thompson A, Collins M, Venier E, Cotte L, Laguno Centeno M, et al. Effectiveness and safety of glecaprevir/pibrentasvir for 8 weeks in the
Grishma H, Bettina H, Chien-Hung C et al, on behalf of the RETRACT-B study group. Am J Gastroenterol, 2024 DOI: 10.14309/ajg.0000000000002759 Πατώντας ΕΔΩ μπορείτε να
https://doi.org/10.1111/apt.17908 Hofer BC et al, AP&T 2024 Πατώντας ΕΔΩ μπορείτε να δείτε την περίληψη του άρθρου
Wang B, Zhou J, Wu X, Sun Y, Li L, Li P, et al. Carvedilol Plus NUC for Patients With HBV-Compensated Cirrhosis Under Virological Suppression: